Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases

REFERENCES

• Bejcek, B. E., D. Y. Li, and T. F. Deuel. 1989. Transformation by v-sis occurs by an internal autoactivation mechanism. Science 245:1496–1499.
   PubMed Web of Science ®Google Scholar
• Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553.
   PubMed Web of Science ®Google Scholar
• Charest, A., V. Kheifets, J. Park, K. Lane, K. McMahon, C. L. Nutt, and D. Housman. 2003. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc. Natl. Acad. Sci. USA 100:916–921.
   PubMed Web of Science ®Google Scholar
• Ellgaard, L., and A. Helenius. 2003. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4:181–191.
   PubMed Web of Science ®Google Scholar
• Frangioni, J. V., P. H. Beahm, V. Shifrin, C. A. Jost, and B. G. Neel. 1992. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 68:545–560.
   PubMed Web of Science ®Google Scholar
• Frangioni, J. V., A. Oda, M. Smith, E. W. Salzman, and B. G. Neel. 1993. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J. 12:4843–4856.
   PubMed Web of Science ®Google Scholar
• George, P., P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, L. Moscinski, and K. Bhalla. 2004. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 64:3645–3652.
   PubMed Web of Science ®Google Scholar
• Hansen, K., M. Johnell, A. Siegbahn, C. Rorsman, U. Engström, C. Wernstedt, C. H. Heldin, and L. Rönnstrand. 1996. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 15:5299–5313.
   PubMed Web of Science ®Google Scholar
• Helenius, A., and M. Aebi. 2001. Intracellular functions of N-linked glycans. Science 291:2364–2369.
   PubMed Web of Science ®Google Scholar
• Helenius, A., and M. Aebi. 2004. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73:1019–1049.
   PubMed Web of Science ®Google Scholar
• Hubbard, S. R. 2002. Autoinhibitory mechanisms in receptor tyrosine kinases. Front. Biosci. 7:d330–d340.
   PubMed Web of Science ®Google Scholar
• Kamal, A., M. F. Boehm, and F. J. Burrows. 2004. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10:283–290.
   PubMed Web of Science ®Google Scholar
• Keating, M. T., and L. T. Williams. 1988. Autocrine stimulation of intracellular PDGF receptors in v-sis-transformed cells. Science 239:914–916.
   PubMed Web of Science ®Google Scholar
• Keilhack, H., U. Hellman, J. van Hengel, F. van Roy, J. Godovac-Zimmermann, and F. D. Böhmer. 2000. The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates p120 catenin. J. Biol. Chem. 275:26376–26384.
   PubMedGoogle Scholar
• Keilhack, H., M. Müller, S. A. Böhmer, C. Frank, K. M. Weidner, W. Birchmeier, T. Ligensa, A. Berndt, H. Kosmehl, B. Günther, T. Müller, C. Birchmeier, and F. D. Böhmer. 2001. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J. Cell Biol. 152:325–334.
   PubMed Web of Science ®Google Scholar
• Kjaer, S., and C. F. Ibanez. 2003. Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. Hum. Mol. Genet. 12:2133–2144.
   PubMedGoogle Scholar
• Levis, M., J. Allebach, K. F. Tse, R. Zheng, B. R. Baldwin, B. D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, and D. Small. 2002. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99:3885–3891.
   PubMed Web of Science ®Google Scholar
• Lievens, P. M., C. Mutinelli, D. Baynes, and E. Liboi. 2004. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J. Biol. Chem. 279:43254–43260.
   PubMedGoogle Scholar
• Linnekin, D., C. S. DeBerry, and S. Mou. 1997. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J. Biol. Chem. 272:27450–27455.
   PubMed Web of Science ®Google Scholar
• Lorenzen, J. A., C. Y. Dadabay, and E. H. Fischer. 1995. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J. Cell Biol. 131:631–643.
   PubMedGoogle Scholar
• Lyman, S. D., L. James, J. Zappone, P. R. Sleath, M. P. Beckmann, and T. Bird. 1993. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene 8:815–822.
   PubMed Web of Science ®Google Scholar
• Matthews, W., C. T. Jordan, G. W. Wiegand, D. Pardoll, and I. R. Lemischka. 1991. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143–1152.
   PubMed Web of Science ®Google Scholar
• Mezzacasa, A., and A. Helenius. 2002. The transitional ER defines a boundary for quality control in the secretion of tsO45 VSV glycoprotein. Traffic 3:833–849.
   PubMed Web of Science ®Google Scholar
• Minami, Y., H. Kiyoi, Y. Yamamoto, K. Yamamoto, R. Ueda, H. Saito, and T. Naoe. 2002. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 16:1535–1540.
   PubMed Web of Science ®Google Scholar
• Mizuki, M., R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C. Müller, W. Gruning, K. Kratz-Albers, S. Serve, C. Steur, T. Buchner, J. Kienast, Y. Kanakura, W. E. Berdel, and H. Serve. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907–3914.
   PubMed Web of Science ®Google Scholar
• Mizuki, M., J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Böhmer, C. Muller-Tidow, W. E. Berdel, and H. Serve. 2003. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 101:3164–3173.
   PubMed Web of Science ®Google Scholar
• Mori, S., L. Rönnstrand, K. Yokote, A. Engstrom, S. A. Courtneidge, L. Claesson-Welsh, and C. H. Heldin. 1993. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 12:2257–2264.
   PubMed Web of Science ®Google Scholar
• Nakao, M., S. Yokota, T. Iwai, H. Kaneko, S. Horiike, K. Kashima, Y. Sonoda, T. Fujimoto, and S. Misawa. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–1918.
   PubMed Web of Science ®Google Scholar
• O'Farrell, A. M., T. J. Abrams, H. A. Yuen, T. J. Ngai, S. G. Louie, K. W. Yee, L. M. Wong, W. Hong, L. B. Lee, A. Town, B. D. Smolich, W. C. Manning, L. J. Murray, M. C. Heinrich, and J. M. Cherrington. 2003. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605.
   PubMed Web of Science ®Google Scholar
• Reith, A. D., C. Ellis, S. D. Lyman, D. M. Anderson, D. E. Williams, A. Bernstein, and T. Pawson. 1991. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 10:2451–2459.
   PubMed Web of Science ®Google Scholar
• Rouard, M., J. Bass, F. Grigorescu, T. P. Garrett, C. W. Ward, G. Lipkind, C. Jaffiole, D. F. Steiner, and G. I. Bell. 1999. Congenital insulin resistance associated with a conformational alteration in a conserved beta-sheet in the insulin receptor L1 domain. J. Biol. Chem. 274:18487–18491.
   PubMedGoogle Scholar
• Sanders, C. R., and J. K. Myers. 2004. Disease-related misassembly of membrane proteins. Annu. Rev. Biophys. Biomol. Struct. 33:25–51.
   PubMedGoogle Scholar
• Sawyers, C. L. 2002. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell. 1:413–415.
   PubMed Web of Science ®Google Scholar
• Scheijen, B., H. T. Ngo, H. Kang, and J. D. Griffin. 2004. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 23:3338–3349.
   PubMed Web of Science ®Google Scholar
• Schmidt-Arras, D., J. Schwäble, F. D. Böhmer, and H. Serve. 2004. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr. Pharm. Des. 10:1867–1883.
   PubMed Web of Science ®Google Scholar
• Shibuya, N., I. J. Goldstein, E. J. Van Damme, and W. J. Peumans. 1988. Binding properties of a mannose-specific lectin from the snowdrop (Galanthus nivalis) bulb. J. Biol. Chem. 263:728–734.
   PubMed Web of Science ®Google Scholar
• Tenev, T., S. A. Böhmer, R. Kaufmann, S. Frese, T. Bittorf, T. Beckers, and F. D. Böhmer. 2000. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur. J. Cell Biol. 79:261–271.
   PubMedGoogle Scholar
• Thiede, C., C. Steudel, B. Mohr, M. Schaich, U. Schakel, U. Platzbecker, M. Wermke, M. Bornhauser, M. Ritter, A. Neubauer, G. Ehninger, and T. Illmer. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326–4335.
   PubMed Web of Science ®Google Scholar
• Tse, K. F., E. Novelli, C. I. Civin, F. D. Böhmer, and D. Small. 2001. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 15:1001–1010.
   PubMed Web of Science ®Google Scholar
• Wasilenko, W. J., D. M. Payne, D. L. Fitzgerald, and M. J. Weber. 1991. Phosphorylation and activation of epidermal growth factor receptors in cells transformed by the src oncogene. Mol. Cell. Biol. 11:309–321.
   PubMedGoogle Scholar
• Waugh, M. G., D. Lawson, and J. J. Hsuan. 1999. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. Biochem. J. 337:591–597.
   PubMedGoogle Scholar
• Weisberg, E., C. Boulton, L. M. Kelly, P. Manley, D. Fabbro, T. Meyer, D. G. Gilliland, and J. D. Griffin. 2002. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1:433–443.
   PubMed Web of Science ®Google Scholar
• Yee, K. W., A. M. O'Farrell, B. D. Smolich, J. M. Cherrington, G. McMahon, C. L. Wait, L. S. McGreevey, D. J. Griffith, and M. C. Heinrich. 2002. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100:2941–2949.
   PubMed Web of Science ®Google Scholar
• Yi, T. L., J. L. Cleveland, and J. N. Ihle. 1992. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol. Cell. Biol. 12:836–846.
   PubMedGoogle Scholar
• Zhen, Y., R. M. Caprioli, and J. V. Staros. 2003. Characterization of glycosylation sites of the epidermal growth factor receptor. Biochemistry 42:5478–5492.
   PubMedGoogle Scholar